{
    "id": "8c54cb6e-c89e-4613-81f3-cd24467fd163",
    "indications": {
        "text": "desvenlafaxine extended-release tablet indicated treatment adults major depressive disorder ( mdd ) [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose : 50 mg daily without food ( 2.1 ) . evidence doses greater 50 mg per day confer additional benefit ( 2.1 ) . 25 mg per day dose intended gradual reduction dose discontinuing treatment dosing severe renal end-stage renal disease patients ( 2.1 ) . discontinuation : reduce dose gradually whenever possible ( 2.1 ) . take tablets whole ; divide , crush , chew , dissolve ( 2.1 ) . moderate renal impairment : maximum dose 50 mg per day ( 2.2 ) . severe renal impairment end-stage renal disease : maximum dose 25 mg per day 50 mg every day ( 2.2 ) . moderate severe hepatic impairment : maximum dose 100 mg per day ( 2.3 ) .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "severe renal end",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_42738"
            }
        ]
    },
    "warningsAndPrecautions": "desvenlafaxine extended-release tablets available follows : 25 mg , tan , biconvex , round shaped film-coated tablets , debossed `` lu `` one side `` s67 `` side . ndc 68180-604-06 , bottle 30 tablets unit-of-use package 50 mg , light pink , biconvex , round shaped film-coated tablets , debossed `` lu `` one side `` s61 `` side . ndc 68180-592-06 , bottle 30 tablets unit-of-use package 100 mg , reddish-orange , biconvex , round shaped film-coated tablets , debossed `` lu `` one side `` s62 `` side . ndc 68180-593-06 , bottle 30 tablets unit-of-use package store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . tablet contains 38 mg , 76 mg 152 mg desvenlafaxine succinate monohydrate equivalent 25 mg , 50 mg 100 mg desvenlafaxine , respectively .",
    "adverseReactions": "hypersensitivity desvenlafaxine succinate , venlafaxine hydrochloride excipients desvenlafaxine formulation . angioedema reported patients treated desvenlafaxine [ ( 6.1 ) ] . maois intended treat psychiatric disorders desvenlafaxine within 7 days stopping treatment desvenlafaxine contraindicated increased risk serotonin syndrome . desvenlafaxine within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.7 ) ( 5.2 ) ] . starting desvenlafaxine patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.8 ) ( 5.2 ) ] .",
    "ingredients": [
        {
            "name": "DESVENLAFAXINE SUCCINATE",
            "code": "ZB22ENF0XR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26806"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        }
    ],
    "organization": "Lupin Pharmaceuticals, Inc.",
    "name": "Desvenlafaxine Succinate",
    "effectiveTime": "20250130",
    "indications_original": "Desvenlafaxine extended-release tablet is indicated for the treatment of adults with major depressive disorder (MDD) [see CLINICAL STUDIES (14)].",
    "contraindications_original": "Recommended dose: 50 mg once daily with or without food ( 2.1 ). There was no evidence that doses greater than 50 mg per day confer any additional benefit ( 2.1 ). The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients ( 2.1 ). Discontinuation: Reduce dose gradually whenever possible ( 2.1 ). Take tablets whole; do not divide, crush, chew, or dissolve ( 2.1 ). Moderate renal impairment: Maximum dose 50 mg per day ( 2.2 ). Severe renal impairment and end-stage renal disease: Maximum dose 25 mg per day or 50 mg every other day ( 2.2 ). Moderate to severe hepatic impairment: Maximum dose 100 mg per day ( 2.3 ).",
    "warningsAndPrecautions_original": "Desvenlafaxine extended-release tablets are available as follows:\n                  \n                     25 mg, tan, biconvex, round shaped film-coated tablets, debossed with \"LU\" on one side and \"S67\" on the other side.\n                  \n                  NDC 68180-604-06, bottle of 30 tablets in unit-of-use package\n                  \n                     50 mg, light pink, biconvex, round shaped film-coated tablets, debossed with \"LU\" on one side and \"S61\" on the other side.\n                  \n                  NDC 68180-592-06, bottle of 30 tablets in unit-of-use package\n                  \n                     100 mg, reddish-orange, biconvex, round shaped film-coated tablets, debossed with \"LU\" on one side and \"S62\" on the other side.\n                  \n                  NDC 68180-593-06, bottle of 30 tablets in unit-of-use package\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate monohydrate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively.",
    "adverseReactions_original": "Hypersensitivity to desvenlafaxine succinate,      venlafaxine hydrochloride or to any excipients in the desvenlafaxine formulation.      Angioedema has been reported in patients treated with desvenlafaxine [see      ADVERSE REACTIONS (6.1)].\n                     \n                     The use of MAOIs intended to treat psychiatric      disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine      is contraindicated because of an increased risk of serotonin syndrome. The      use of desvenlafaxine within 14 days of stopping an MAOI intended to treat      psychiatric disorders is also contraindicated [see DOSAGE AND      ADMINISTRATION (2.7) and WARNINGS AND      PRECAUTIONS (5.2)].\n                     \n                     Starting desvenlafaxine in a patient who is being      treated with MAOIs such as linezolid or intravenous methylene blue is also      contraindicated because of an increased risk of serotonin syndrome [see      DOSAGE AND ADMINISTRATION (2.8) and WARNINGS      AND PRECAUTIONS (5.2)].",
    "drug": [
        {
            "name": "Desvenlafaxine Succinate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26806"
        }
    ]
}